Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julian Gray

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Current Opinion in Molecular Therapeutics|July 23, 2003
Protein microarray technology for unraveling the antibody specificity repertoire against microbial proteomesTito Bacarese-Hamilton, Julian Gray, Andrea Crisanti
Current Opinion in Investigational Drugs (London, England : 2000)|June 24, 2010
Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trialsRobert A McArthur, Julian Gray, Rudy Schreiber
Methods in Molecular Biology (Clifton, N.J.)|March 17, 2004
Protein arrays for serodiagnosis of diseaseTito Bacarese-Hamilton, Andrea Ardizzoni, Julian Gray, et al.
Methods in Molecular Medicine|September 15, 2005
Allergen microarraysTito Bacarese-Hamilton, Julian Gray, Andrea Ardizzoni, et al.
Malaria Journal|April 19, 2015
Asymptomatic Plasmodium falciparum infection in children is associated with increased auto-antibody production, high IL-10 plasma levels and antibodies to merozoite surface protein 3Vincent Guiyedi, Christophe Bécavin, Fabien Herbert, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 24, 2012
Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety studyBruno Dubois, Eduardo Tolosa, Regina Katzenschlager, et al.
Pharmacological Research|June 15, 2020
Rimeporide as a first- in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with Duchenne Muscular DystrophyStefano C Previtali, Teresa Gidaro, Jordi Díaz-Manera, et al.
Ebiomedicine|September 19, 2025
Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase 1b/2a, multicentre, double-blind, randomised, placebo-controlled studyOlivier Sol, Julien Mermoud, Merja Hallikainen, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Current Opinion in Molecular Therapeutics|July 23, 2003
Protein microarray technology for unraveling the antibody specificity repertoire against microbial proteomesTito Bacarese-Hamilton, Julian Gray, Andrea Crisanti
Current Opinion in Investigational Drugs (London, England : 2000)|June 24, 2010
Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trialsRobert A McArthur, Julian Gray, Rudy Schreiber
Methods in Molecular Biology (Clifton, N.J.)|March 17, 2004
Protein arrays for serodiagnosis of diseaseTito Bacarese-Hamilton, Andrea Ardizzoni, Julian Gray, et al.
Methods in Molecular Medicine|September 15, 2005
Allergen microarraysTito Bacarese-Hamilton, Julian Gray, Andrea Ardizzoni, et al.
Malaria Journal|April 19, 2015
Asymptomatic Plasmodium falciparum infection in children is associated with increased auto-antibody production, high IL-10 plasma levels and antibodies to merozoite surface protein 3Vincent Guiyedi, Christophe Bécavin, Fabien Herbert, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 24, 2012
Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety studyBruno Dubois, Eduardo Tolosa, Regina Katzenschlager, et al.
Pharmacological Research|June 15, 2020
Rimeporide as a first- in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with Duchenne Muscular DystrophyStefano C Previtali, Teresa Gidaro, Jordi Díaz-Manera, et al.
Ebiomedicine|September 19, 2025
Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase 1b/2a, multicentre, double-blind, randomised, placebo-controlled studyOlivier Sol, Julien Mermoud, Merja Hallikainen, et al.
Pageof 1